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Summary 
 IL-7 supports host immunity in lymphopenic and immunosuppressed patients and expand 
tumor-reactive T cells for adoptive immunotherapy. Here, we report that IL-7 also enables 
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the accumulation of clinically-relevant pathogen-reactive T cells from TB, CMV, and 
Candida albicans infected individuals. 
 
Abstract 
 
BACKGROUND: IL-7 promotes the generation, expansion and survival of memory T cells. 
Previous mouse and human studies showed that IL-7 can support immune cell reconstitution in 
lymphopenic conditions, expand tumor-reactive T cells for adoptive immunotherapy and enhance 
effector cytokine expression by autoreactive T cells. Whether pathogen-reactive T cells also benefit 
from IL-7 exposure remains unknown. METHODS: Here we investigated this issue in cultures of 
peripheral blood mononuclear cells (PBMCs) derived from patients infected with various endemic 
pathogens. After short-term exposure to IL-7, we measured PBMC responses to antigens (Ag) 
derived from pathogens, such as Mycobacterium tuberculosis (MTB), Candida albicans (Ca) and 
Cytomegalovirus (CMV), and to the superantigen Staphylococcus aureus enterotoxin B (SEB). 
RESULTS: We found that IL-7 favoured the expansion and, in some instances, the uncovering of 
pathogen-reactive CD4 T cells, by promoting pathogen-specific IFNɣ, IL-2 and TNF recall 
responses. CONCLUSIONS: Our findings indicate that IL-7 unveils and supports re-activation of 
pathogen-specific T cells with possible diagnostic, prognostic and therapeutic significance, of 
clinical value especially in conditions of pathogen persistence and chronic infection.  
 
Keywords: IL-7; pathogen-specific responses; memory T cells; polyfunctional T cells; TB infection; 
candida infection; CMV infection; SEB responses; in vivo priming; T cell expansion. 
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 Abbreviations used in the text: IL-: interleukin; Ag: antigen; MTB: Mycobaterium 
tuberculosis; Ca: Candida albicans; CMV: Cytomegalovirus; SEB: Staphylococcus aureus 
enterotoxin B;  TNF: tumor necrosis factor; IFN: interferon; IL-7R: interleukin-7 receptor; 
PBMCs: peripheral blood mononuclear cells; TCM: central memory T cells; TEM: effector 
memory T cells; TSCM: stem-cell memory T cells; TCR: T cell receptor; Th-: T helper cell; 
ACT: adoptive T cell therapy; HIV: human immunodeficiency virus; SIV: simian 
Downloaded from https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiy096/4913790
by University of Sussex user
on 06 March 2018
Ac
ce
pte
d M
an
us
cri
pt
 
4 
 
immunodeficiency virus; TB: tuberculosis; TST: tuberculin skin test; MTP: Mycobaterium 
tuberculosis-specific peptides; BCG: Bacillus Calmette Guarin; APCs: antigen-presenting 
cells; CMV-: Cytomegalovirus-seronegative; CMV+: Cytomegalovirus-seropositive; PBS: 
phosphate-buffered saline; AICD: activation-induced cell death; FCS: fetal calf serum; 
RPMI: Roswell Park Memorial Institute medium; CFSE: 5-(and-6)-carboxyfluorescein 
diacetate succinimilyl ester; CSA: cyclosporine A; ELISPOT: enzyme-linked immuno-spot assay; SFC: 
spot forming cell; ICS: intracellular cytokine staining; mAb: monoclonal antibody. 
 
Introduction 
IL-7[1] is a pleiotropic cytokine[2] regulating lymphopoiesis and T cell homeostasis[3, 4]. It 
binds to a heterodimeric receptor formed by an alpha-chain (CD127[3]), which is private to the IL-7 
receptor (IL-7R) and the common-ɣ-chain cytokine-receptor (CD132[5, 6]). In humans, mutations 
negatively affecting the levels of CD127 have been correlated with severe immunodeficiency[7]. 
Conversely, increased serum levels of IL-7 and/or dysregulated activation of CD127 are reported in 
patients with autoimmune conditions, including multiple sclerosis[8, 9], rheumatoid arthritis[10], 
type-I diabetes[11], inflammatory bowel disease[12] and psoriasis[13]. 
Upon antigen encounter, IL-7 sustains the generation of memory T lymphocytes in vitro[14] 
and in vivo[14-16] and favors the transition of effector to central memory cells[17, 18] while driving 
their proliferation[19]. Via the JAK3/STAT5 pathway and the upregulation of anti-apoptotic factors 
(e.g., Bcl-2)[14, 20], IL-7 promotes the long-term survival of naïve and memory-phenotype cells. 
Recombinant IL-7 elicits a marked increase of central memory (TCM) and effector memory T cells 
(TEM) when administered to aged non-human primates[21], and lymphopenic patients and 
macaques infected with HIV or SIV respectively[22-24]. Similar effects are reported in patients 
undergoing stem cell transplantation[25, 26], where IL-7 levels correlate with the generation of 
stem-cell memory T cells (TSCM)[26]. In cancer patients, IL-7 preferentially increases naïve, but not 
regulatory T cell numbers[27], maintaining T cell receptor (TCR) repertoire diversity[28]. Hence, the 
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immunotherapeutic use of IL-7 is increasingly proposed to favor immune-cell reconstitution and 
function after lympho-depleting chemotherapy or in the elderly. In the setting of adoptive T cell 
therapy (ACT), IL-7 has been used in primary cultures to engineer and expand tumor-reactive T 
cells[29, 30]. We previously found that IL-7 selectively expands tumor-reactive CD4 T cells capable 
of promoting tumor protection in ACT[29]. Whether similar results could be extendible to pathogen-
specific T cells remains unknown. We therefore sought to investigate the expansion of pathogen-
reactive CD4 T cells in individuals affected by recurrent or persistent/chronic bacterial 
(Mycobacterium tuberculosis, MTB and Staphylococcus aureus), fungal (Candida albicans, Ca) or 
viral (Cytomegalovirus, CMV) infections. We report that, in all cases, IL-7 enriched pathogen-
specific CD4 T cells, enabling their detection and sensitizing them to antigen-specific recall 
responses. Further, IL-7 rescued chronically activated pathogen-specific effectors enhancing their 
Ag-recall responses. We believe that these data open new avenues for diagnostic, prognostic and 
therapeutic applications. 
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Materials and Methods 
 
Classification of TB patients. 
HIV-seronegative patients with active TB (clinic and culture confirmed) were recruited at the 
Clinic of Infectious Diseases, San Raffaele Hospital (Milan, Italy). They underwent TST 
administered by the Mantoux method with 0.1 ml (5 tuberculin units) of Biocinetest-PPD tuberculin 
(Chiron Italia, Milan, Italy). The size of induration was evaluated after 48-72 hours (an induration 
10 mm was classified as positive). Peripheral blood was withdrawn before starting any therapy 
and under a written informed consent. Healthy controls were selected among HIV-seronegative 
individuals with no history of TB exposure, no infection and with negative reaction to the TST. 
Healthy controls were tested for the presence of Ca-Ag responses.  
 
Ethics Statement. 
Written informed consent or consultee approval to enroll was secured for all study 
participants (patients and healthy donors). This study was approved by the Ethical Committee of 
the San Raffaele Scientific Institute, the UK National Research Ethics Service (NRES) (reference: 
13/LO/1270) and the BSMS Research Governance and Ethics Committee (reference: 13/182/LLE) 
and carried out in accordance with the approved guidelines. All data were anonymized. 
 
CMV serology. 
Healthy donors were screened for the presence of CMV-specific antibody in serum. CMV 
IgG serology (Architect CMV IgG, Abbot, Maidenhead, UK) was performed at the Brighton and 
Sussex University Hospital Trust (BSUHT) virology laboratory. CMV-seropositive and seronegative 
individuals are referred to as CMV+ and CMV-, respectively.  
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Human samples and T cell cultures. 
Patients and healthy donors used for MTB- and Candida-specific responses were part of a 
previously published cohort[31]. Donors (male:female, 10:9) used for CMV and SEB-specific 
responses were 68±17 years old. PBMCs were isolated by blood centrifugation over Ficoll-
Hypaque (Sigma/Merck, Darmstadt, Germany) density gradient. Cultures were derived either from 
freshly-isolated (CMV/SEB responses) or cryopreserved (90% fetal calf serum, FCS, and 10% 
DMSO; MTB/Ca-Ag responses) PBMCs. Equal numbers of viable (0.1% Trypan Blue-negative) 
cells were resuspended in complete media (RPMI containing penicillin, streptomycin, glutamine 
and 10% FCS –all from ThermoFisherScientific- or autologous serum) with or without human 
recombinant IL-7 (50 ng/ml, unless specified otherwise in individual figures; R&D 
Systems/Biotechne, Minneapolis, USA) for 7 days. Where indicated, cells were stained with the 
fluorescent dye 5-(and-6)-carboxyfluorescein diacetate succinimidyl ester (CFSE, 
ThermoFisherScientific; 1 µM) as by manufacturer instructions, using autologous serum or FCS to 
quench the labelling. Where indicated, cells were first cultured in complete medium with or without 
bacterial Staphylococcus aureus enteroxin B (SEB, 1g/ml, Sigma/Merck). After 5 days, cells were 
harvested, washed and counted. Equal number of viable cells were finally seeded in culture with or 
without IL-7, for additional 7 days (day 12). CSA (0.5 µg/ml, Calbiochem/Merck) or anti-LFA-1 
blocking antibody (5 µg/ml, a gift from Prof Ruggero Pardi, University Vita-Salute San Raffaele, 
Milan) were added to the cultures. 
  
 
MTP– and Ca-Ag-specific ELISPOT assay.  
The ELISPOT for IFNɣ detection was performed as before[31]. Briefly, equal numbers of 
viable cells (5x104 cells/well) were seeded in duplicate in 96-well plates (MAIPS4510; 
Millipore/Merck), pre-coated with anti-IFNɣ capture mAb (B-B1; Diaclone, Besançon, France), 
together with autologous irradiated PBMCs (5x104 cells/well) and Mycobacterium tuberculosis 
peptides (MTPs, a pool of six synthetic peptides; 2 µg/ml per peptide; Primm, Milan, Italy; Ca-Ag, 
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25 µg/ml; Bio-Rad, Hercules, USA)  for 18hrs at 37°C in 5% CO2 atmosphere. Biotinylated anti-
IFNɣ detection mAb (B-G1; Diaclone) was added (4h), followed by the streptavidin-alkaline 
phosphatase conjugate (Amersham Pharmacia Biotech Europe GmbH, Freiburg, Germany; 1h). 
After a washing step, the nitroblue tetrazolium-BCIP (5-bromo-4-chloro-3-indolylphosphate; Sigma) 
chromogenic substrate was added. Individual spot forming cells (SFC) were counted using an 
automated image analysis system ELISPOT reader (AID-GmbH, Strassberg, Germany). MTPs (20 
amino-acids) were derived from the ESAT-6 and CFP-10 secretory proteins of MTB, purified 
(>70%) and previously validated[31]. PBMCs in medium alone or stimulated with 
phytohemagglutinin (PHA-P; Sigma; 5 µg/ml) were used to assess assay background and 
functionality.  
 
Flow Cytometry analysis and intracellular cytokine staining (ICS). 
Cells were harvested, washed with staining buffer (PBS supplemented with 0.5% FCS and 
0.02% NaN3) and incubated with monoclonal antibodies directed against surface Ags for 15 
minutes at room temperature. The following fluorescence-conjugated monoclonal antibodies 
(mAbs) were used: anti-CD3-v500, anti-CD8-Allophyocyanine(APC)-H7, anti-CD27-
Phycoerythrine(PE), IL-2-Fluorescein-iso-thio-cyanate(FITC), TNFα Alexa700, (all from BD 
Biosciences, New Jersey, USA), anti-CD4-Peridinin chlorophyll(PerCP), anti-IFN PE-
Cy7(Cyanine-7), anti-CD154 Pacific-Blue (BioLegend, Cambridge, UK), anti-CD45RA ECD 
(Beckman Coulter, UK) and Yellow live-dead stain (ThermoFisherScientific). Thereafter, cells were 
washed in staining buffer prior to acquisition.  
ICS was used to measure MTP-specific cytokine release at single-cell level. Equal numbers 
of CFSE-labeled cytokine-cultured cells (0.6x106) were stimulated (6hrs) with unpulsed (nil) or 
MTP-pulsed (4 µg/ml) autologous irradiated (5000 rad) PBMCs (3x106 cells), in the presence of 
human anti-CD28-stimulating mAb (2 µg/ml, BD Biosciences). In the last 5hrs of stimulation, 
Brefeldin A (10 µg/ml, Sigma) was added. To measure CMV-/SEB-specific cytokine release, equal 
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numbers of cells were stimulated with CMV lysate (2 µg/ml; Advanced Biotechnologies, 
Eldersburg, USA) or SEB (1 µg/ml) for 2hrs followed by 14hrs in the presence of Brefeldin A. 
Thereafter, cells were washed, surface-stained as described above, fixed, permeabilized and 
stained with anti-CD4, anti-IL-2, anti-IFNɣ and/or anti-TNFα mAbs. Events were acquired on a BD 
FACSCalibur or LSRII and data were analysed using the FlowJo-v9.x software (TreeStar Inc., 
Ashland, USA).  
 
Statistical analysis. 
GraphPad Prism 7.03 was used for statistical analyses. The D’Agostino and Pearson and 
the Shapiro-Wilk tests were used to determine normality of data distribution. Only for normally 
distributed data that passed both tests, means and standard deviation (SD) are shown and paired 
t-tests are used to compare 2 groups. For not-normally distributed data, non-parametric paired 
tests (Wilcoxon test) were used to compare 2 groups. For multiple-group comparisons, 2-way 
ANOVA with Sidak’s or Tukey’s multiple comparison corrections were used, as indicated in the 
figures. Levels of significance are: *, p≤0.05; **, p≤0.005; and ***, p≤0.0005, unless specified 
differently in individual figures. 
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Results  
IL-7 enhances recall responses and proliferation of MTB-specific CD4+ T cells.  
To investigate putative effects of IL-7 on pathogen-specific T cells, we first analyzed 
chronically infected tuberculosis (TB) patients. These were chosen based on clinical history and 
manifestation of acute MTB infection (clinic and culture confirmed), positive reaction to the 
tuberculin skin test (TST) and ability of PBMCs to respond to a stimulation with MHC-II-restricted 
MTB-specific promiscuous peptides (MTPs) in IFNɣ ELISPOT assays[31]. Patients with detectable 
(Pt#1 and Pt#2, Fig. 1) or undetectable (Pt#3, Fig.1) MTB-specific IFNɣ producing T cells were 
analyzed. Cryopreserved cells were tested in MTP-recall assays immediately after thawing (d0, 
Fig. 1A-B) or at the end of a culture (d7) in IL-7 compared to complete media (med). Not all 
patients with detectable MTP-specific T cell responses on fresh PBMCs[31] had a detectable MTP-
response after thawing, as seen in the case of Pt#2, compared to Pt#1. Nonetheless, we found 
that IL-7 selectively enriched cultures for MTP-specific IFNɣ+ T cells by 4-10 fold in all cases (Fig. 
1B). While MTP-specific T cells  could expand also in control cultures (as seen for Pt#1, med), this 
was best explained by the increase of total CD3+CD4+ T cells in some patients (not shown). 
Significantly, the frequency of MTP-specific cells increased in IL-7 cultures over the levels found in 
control cultures, even if the percentage of total CD3+CD4+ T cells remained similar. Of note, IL-7 
also allowed us to detect MTP-specific T cells in samples derived from immunosuppressed 
patients (i.e. anergic, Pt#3). Sensitization with IL-7 significantly increased absolute numbers of 
MTP-specific T cells in all the TB patients analyzed (Fig. 1C, n=5) compared to non-BCG (Bacillus 
Calmette Guarin) vaccinated healthy donors (non-MTB-infected controls, n=8). 
To independently confirm the presence of MTP-specific T cells, we additionally performed ICS after 
MTP stimulation. MTP-pulsed irradiated autologous PBMCs were used as Ag-presenting cells 
(APCs).  As with ELISPOT assays, in ICS we found that the frequency of MTP-specific, IL-2+IFNɣ+ 
CD4 T cells increased in IL-7 cultures, compared to freshly thawed PMBCs (d0) and control 
cultures (med, Supplementary Fig. 1).  
Thus, MTB-specific T cell recall responses are enhanced after sensitization with IL-7. 
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IL-7 supports fungal and viral-specific CD4 T cell accumulation in PBMCs from 
infected individuals.  
We then asked whether exposure to IL-7 would also enable the accumulation of CD4 T 
cells specific for fungal Ags derived from endemic pathogens, such as Ca. Freshly thawed PBMCs 
derived from individuals with recurrent Ca-infections were immediately analyzed for IFNɣ 
expression in Ca-Ag-recall ELISPOT, in the presence of Ag-pulsed irradiated autologous PBMCs 
as APCs (d0, Fig. 2), or seeded in culture with or without IL-7 (Fig. 2, d7 and med, respectively), 
and analyzed after 7 days. As in the case of TB-specific T cells, also Ca-Ag-specific, IFNɣ spots 
were remarkably increased in IL-7-driven cultures, compared to controls (d0 and med; Fig 2A). In 
multiple individuals (n=4), Ca-Ag specific effectors were significantly increased by ~10-fold over the 
levels found after thawing (d0) upon IL-7 exposure compared to control medium (Fig. 2B).  
As CMV-specific CD4 T cells have been recently shown to significantly expand in elderly 
individuals chronically infected with the endemic CMV[32, 33], we investigated CMV-specific CD4 
T cell responsiveness to IL-7 in cultures derived from CMV-seropositive (CMV+) patients. CMV-
seronegative (CMV-) individuals were used as controls. Freshly derived PBMCs were cultured in 
the presence of IL-7 or control medium (med) for 7 days, and then CMV-recall responses were 
tested in ICS, using total CMV lysate as a source of viral Ags (Fig. 3A, top). Again, cells cultured in 
IL-7 tended to show higher CMV-recall responses compared to controls (Fig. 3A). Of note, these 
CMV-specific T cells were mostly poly-functional, TNFα+IFNɣ+ producing cells (Fig. 3A) and 
remained undetectable in cultures derived from CMV- individuals (Supplementary Fig. 2A). As we 
found that T cells express varying amounts of CD127 and upregulate it in control medium 
(Supplementary Fig. 2B), as expected[34], we first rested freshly thawed PBMCs for 5 days, and 
then subjected them to IL-7-driven cultures (Fig. 3B, top). Under these conditions, we found that IL-
7 more potently and reproducibly enabled the accumulation of CMV-specific T cell responses from 
CMV+ individuals (Fig. 3C, n=10). IFNɣ+ cells expressed low levels of CD127, indicative of IL-7-
driven receptor down-modulation[34], upon cytokine-driven activation (Fig. 3D), while maintaining 
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high levels of LFA-1 (not shown) and polyfunctional cytokine expression (Fig. 3B). Thus, in addition 
to bacterial also fungal and viral-specific responses are enhanced by IL-7 signals. 
 
IL-7 promotes responsiveness of Staphylococcus aureus specific T cells. 
Bacterial superantigens, such as the Staphylococcus aureus enterotoxin B (SEB), can lead 
to T cell anergy[35] or suppression[36]. We asked whether culturing the cells in IL-7 might also 
help SEB-specific T cell responses (Fig. 4). PBMCs from healthy donors were rested 5 days in 
control medium and then left untreated or cultured in IL-7 for 7 days. SEB-recall responses were 
then tested in ICS (Fig. 4A, top). We found that while SEB-specific T cells could be detected in 
control PBMC cultures (med), IFNɣ+ or TNFα+ and TNFα+IFNɣ+ cells were all enriched for in IL-7-
driven cultures from many individuals, significantly (Fig. 4A-B, n=17). As seen for CMV-specific T 
cells (Fig. 3D), cytokine+ SEB-specific cells expressed lower levels of CD127 (Fig. 4C) while 
maintaining high levels of LFA-1 (not shown).  
We also tested whether IL-7 is capable of supporting SEB-responsiveness even after Ag-
driven expansion, in vitro (Fig. 4D). We found that IL-7 significantly enhanced responses after 
SEB-restimulation (Fig. 4D). Thus, culturing T cells in IL-7 either before or after Ag-recall allows for 
a higher frequency of Ag-specific cells to be identified.  
IL-7 drives cyclosporine A-sensitive TCM cell division.  
In a previous mouse study, we found that IL-7 favored the in vitro expansion of tumor-Ag-
experienced T cells, by promoting their proliferation[29]. Thus, we asked whether IL-7-driven 
accumulation of human, pathogen-specific T cells also requires cell division. To this aim, we set up 
CFSE-labeled PBMC cultures (Fig. 5A-B). We found that while a small fraction of CD4 T cells 
derived from healthy donors (~1-10%) underwent several rounds of “spontaneous” (i.e., in the 
absence of any introduced stimulation) cell-division in complete media (Fig. 5A, top panel), dividing 
cells were dramatically increased upon IL-7 addition (Fig. 5A, bottom panel). These cells 
expressed high levels of Bcl-2 (Supplementary Fig. 3), in agreement with the pro-survival role of 
the cytokine[20]. Importantly, IL-7 favored the expansion of two cell populations, distinguishable for 
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their proliferation potential (i.e., either fast or slow; F and S respectively in the figures) and with 
distinct mechanistic requirements. Indeed, while both populations were best detected in high-
density cell cultures (Supplementary Fig. 4), they proved differentially sensitive to cyclosporine A 
(CSA). Fast- but not slow-dividing cells were sensitive to CSA inhibition (Fig. 5B). Additionally, fast-
dividing cells were sensitive to anti-LFA-1 mAb blockade (Supplementary Fig. 5), suggesting that 
cell-to-cell contacts are also required for their proliferation. Of note, IL-7 elicited similar effects in 
autologous sera and FCS (Supplementary Fig. 4). We reckoned that, while slow-dividing cells 
represent cells undergoing homeostatic expansion, known to occur via CSA-insensitive 
mechanisms[19] (Fig. 5B, right panel in top row), fast-dividing cells may represent a distinct 
population of Ag-experienced memory cells proliferating via a CSA-sensitive mechanism (Fig. 5B, 
middle-right panel in top row). Flow cytometry analysis indicated that while both TCM (CD45RA
-, 
CD62L+) and TEM (CD45RA
-, CD62L-) cells accumulated in response to IL-7 (Fig. 5B middle and 
bottom panel), only fast-dividing TCM (CD45RA
-, CD62L+) cells appeared sensitive to CSA (Fig. 5B, 
bottom panel). Interestingly, the IL-7-driven accumulation of CMV (Fig. 5C, top), SEB (Fig. 5C, 
bottom and right, n=15) and MTB-specific (Supplementary Fig. 6) polyfunctional memory T cells 
was also completely dependent upon CSA-sensitive signaling. Together our data indicate that IL-7-
driven cultures might recapitulate the events accounting for the maintenance of Ag-experienced 
memory T cell subsets in vivo[15], and improve their identification and selection in vitro.   
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Discussion 
In this study, we demonstrate that IL-7 supports the in-vitro expansion of human pathogen-
specific T cells, favoring and, in some instances, enabling their enumeration and characterization. 
IL-7 sensitive pathogen-specific effectors included cells specific for endemically diffused pathogens 
(e.g., Staphylococcus aureus, Candida albicans, CMV and MTB, in parts of the world), infecting 
humans recurrently during the lifetime, persisting (MTB) and/or reactivating in the body (CMV). 
Thus, our data will help the study and isolation of such pathogen-specific T cells and others 
relevant to various clinical settings, including harmful infections, especially in the case of immune-
suppressed (HIV, transplantation, aged etc.) or chronically infected individuals, in which pathogen-
specific T cells might be low in frequency and/or hypo-responsive. 
Previous studies showed that IL-7 can support immune-cell reconstitution in lymphopenic 
conditions[22-25], restore sepsis-induced lymphocyte dysfunctions([37, 38]), enhance effector 
function of autoreactive T cells[8-13], and expand tumor-reactive T cells[29, 30]. We then asked 
whether also pathogen-reactive T cells benefited from IL-7 exposure. Our results show that IL-7 
promoted the selective expansion of a fraction of memory CD4+ T cells containing pathogen-
specific cells, best observed in high cell-density cultures. Although IL-7 significantly enhanced 
overall cell recovery (by ~1.5-fold), cytokine-producing CD4 T cells were not enriched at polyclonal 
level (as detected by PMA and Ionomycin stimulation, Supplementary Fig. 7) unlike seen for 
pathogen-specific cells. These cells showed a fast rate of proliferation, sensitive to CSA and LFA-1 
inhibition, both in autologous sera and FCS. Thus, neither homeostatic cell division[19, 39-42], 
known to be CSA insensitive[19, 42], nor food-related, bovine Ags appear to account for the 
accumulation of fast-dividing cells. Rather, our results suggest the existence of a cell-associated 
ligand capable of synergizing with IL-7 signals to promote the proliferation and responsiveness of 
pathogen-specific T cells. We speculate that self-Ag/TCR-initiated signals may play a role in the IL-
7 cultures.  
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Although further research is needed to identify such signals in IL-7 cultures, our data 
support a role for IL-7 in T cell-driven immunopathology in chronic and persistent infections, co-
infections or autoimmunity. Accordingly, IL-7 is expressed in inflamed tissues of patients with 
(rheumatic) autoimmune diseases, where it can be produced by several cell types[43] (including 
macrophages, dendritic cells, and fibroblasts) and favor pathogenic Th1 and Th17-associated 
cytokine secretion. Furthermore, dysregulated IL-7 expression or activation of CD127 were found 
in patients with autoimmune conditions[8-13], suggesting that IL-7 supports the function of 
pathogenic effector cells in autoimmunity. In agreement, blocking the IL-7R in experimental animal 
models ameliorated autoimmune disease manifestations[44]. Thus, together with available data, 
our results suggest that IL-7 might awaken auto-reactive T cells, or pathogen-specific effector T 
cells with cross-reactivity to self-antigen, hence contributing to autoimmunity. However, this might 
not equally apply to patients with immune dysfunctions due to sepsis or chronic HIV/HCV infection. 
Indeed, IL-7 administration mainly in HIV-infected or immunosuppressed patients was generally 
well-tolerated[22, 23, 25, 27, 28, 45], with a single report of a patient developing systemic lupus 
erythematosus after 3 doses of IL-7[45]. We speculate that the risk of developing autoimmunity 
after IL-7 treatment may vary dependent on individual clinical history, genetic predisposition and 
the administration regimen. Further studies are needed to define the long-term consequences of 
IL-7 administration. 
Interestingly, among memory cells, polyfunctional T cells (double positive for IFNɣ+ and IL-
2+ or TNFα+) were mostly enriched for by IL-7. Such cells were detected in subjects with chronic 
viral (including CMV[32]) infections and previously referred to as intermediate polyfunctional 
memory cells[46]. It is possible that IL-7 favors differentiation of these cells in vitro (and possibly 
also in vivo), starting from IFNɣ-producing cells. With respect to maintaining polyfunctional T cells, 
IL-7 appears superior to the cognate Ag by favoring (central) memory cell survival[15-17], rather 
than terminal differentiation, activation induced cell-death (AICD) and/or exhaustion[29].  Thus, IL-7 
may be useful for the expansion of human polyclonal and polyfunctional pathogen-specific CD4 
(and to a lower extent, CD3+ CD4- or CD8+, Supplementary Fig. 8A-E) T cells hard to be identified, 
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even in the case of relatively well-studied pathogens (such as CMV[47, 48]). Accordingly, exposing 
cells to IL-7 enabled better enumeration of in vivo-primed CMV/SEB-specific cells, although these 
trends were less apparent in CD8+ T cells, which did not undergo fast-proliferation to the extent of 
CD4 T cells (Supplementary Fig. 8F). This was also the case when T cells were Ag-re-stimulated 
in vitro prior to the IL-7 culture, opening the possibility that IL-7 (with or without Ag) might be 
superior to Ag alone in expanding T cells derived from in vivo-primed individuals. Our data also 
support the hypothesis that IL-7 sustains the preferential accumulation of polyfunctional T cell 
subsets within the repertoire of certain individuals, including perhaps the inflated responses of CD4 
T cells detected in old CMV+ individuals[32, 33]. Future studies are needed to address this 
possibility.  
Previously, we suggested that among other CD132-cytokines, IL-7 played non-redundant 
roles and outperformed IL-2 in driving Ag-experienced T cell accumulation and mediating the 
expansion of less differentiated cells useful for gene therapy[26, 30]. We now provide evidence 
supporting the use of IL-7 to reveal and expand  in vivo-primed pathogen-specific lymphocytes of 
clinical relevance, either as biomarkers of viral infection and disease activity[49], or as therapeutic 
tools. This may be relevant for the treatment of chronic infectious diseases and cancer, since 
adoptive immunotherapy with less differentiated T cells is preferable over the transfer of terminally 
differentiated effectors[50]. 
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Figure legends 
Figure 1. IL-7 enhances Mycobacterium tuberculosis-specific T cell responses. A. 
Cryopreserved PBMCs from TB patients were analyzed for IFN- release by MTP-specific 
ELISPOT assay at the time of thawing (d0) and after a 7-day culture in the absence (med, dashed 
line) or in the presence of human recombinant IL-7 (IL-7, solid line), in parallel to unstimulated 
controls (nil). For each patient, 2 duplicate vials were sequentially thawed, staggered in time 
(dashdotted lines): the first vial was used to set up the cultures at d0 (left dashdotted arrow); the 
second vial was thawed 7 days later (right dashdotted arrow) in order to provide for: (i) ex vivo 
control cells to be analyzed in parallel to cultured cells; and (ii) autologous feeder cells for the 
restimulation assays (refer to Materials and Methods for details). B. Background IFN release was 
measured for any condition in Ag-unpulsed control wells (nil), as representatively depicted for Pt. 
#1 (top row). IFN-spots after re-stimulation with MTP promiscuous peptides were detected in 
three TB patients (Pt. #1, #2 and #3) after thawing (d0) and/or a 7-day culture (d7) in IL-7 (IL-7) or 
control medium (med).  C. The effect of the IL-7 treatment (d0 versus d7, IL-7) on MTP-specific 
IFN-spot accumulation in PBMCs derived from healthy donors (open circles, n=8) and MTB-
infected patients (open triangles, n=5) was analyzed by the ELISPOT assay in multiple individuals. 
Statistical significances were evaluated using a 2-way ANOVA with Sidak’s multiple comparison 
correction to evaluate the effect of IL-7 treatment in the two different groups during time, and the 
diagnostic power of the discrimination of the two groups before and after IL-7 treatment, as 
indicated: *, p≤0.05; **, p≤0.005.  
 
Figure 2. IL-7 supports the expansion and effector function of Candida albicans-specific T 
cells.  A. After thawing, PBMCs from a donor with recurrent Candida albicans (Ca) infection were 
analyzed for the release of the effector cytokine, IFN using a Ca-Ag-specific ELISPOT assay at 
the time of thawing (d0) and after a 7-day culture in the absence (d7, med) or in the presence of 
human recombinant IL-7 (d7, IL-7). Background IFN release was measured in Ag-unpulsed 
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control wells (nil, upper wells) in the presence of irradiated autologous feeder cells. B. The range 
and average fold-increase of Ca-Ag-specific IFN-spots in control medium (med vs d0, white bar) 
and IL7 (IL7 vs d0, dotted bar) cultures over the levels found after thawing (d0) is shown. 
Statistically significant accumulation of Ca-Ag-specific IFN-spots was evaluated in multiple donors 
(n=4) using a paired t-test. *p≤0.05; **, p≤0.005; ***, p≤0.0005.  
 
Figure 3. IL-7 supports the accumulation of antiviral CMV-specific T cells.  A. Freshly-derived 
PBMCs from CMV+ donors were analyzed for inflammatory cytokine release after CMV-lysate ICS 
assay after a 7-day culture in the absence (d7, med, dashed black line) or in the presence of 
human recombinant IL-7 (d7, IL-7, black line). Left and right dot plots show the levels of IL-2 and 
TNF or IFN-, and TNF in gated CD4 T cells, respectively. Background levels of cytokine 
secretion were typically measured in unstimulated controls (nil). B. Freshly isolated PBMCs from 
CMV+ donors were rested for 5 days in plain medium (dashed black line) prior to a 7-day culture in 
the absence (d12, med, dashed black line) or in the presence of human recombinant IL-7 (d12, IL-
7, black line). At day 12 (d12), CD4+ T cells were analyzed for IFN- and TNF release (top row) 
alongside expression of CD127 (bottom row), after CMV-lysate ICS assay. CMV-specific IFN-+ 
CD4+ T cells show high CD127 expression in the resting cultures whilst they downregulated CD127 
expression upon exposure to IL-7. Background levels of cytokine secretion were typically 
measured in ICS unstimulated (nil) controls. A representative of >10 independent experiments is 
shown. C. After subtraction of individual background levels of IFN-+ and TNF+andIFN-+TNF+ 
CD4 T cells detected in unstimulated controls (nil), the percentage of CMV-specific cytokine+ (IFN-
+ and TNF+) CD4 T cells was evaluated in 10 independent CMV+ donors in IL-7 (IL-7, open 
triangles) compared to control medium (med, open circles) cultures. The graph shows a statistically 
significant (paired Wilcoxon test, *p=0.03) increase of the frequency (Log10) of CMV-specific CD4 
T cells after IL-7 culture. D. CD127 expression (Log10 MFI, mean fluorescence intensity) is 
significantly downregulated in CMV-specific IFN-+ CD4+ T cells exposed to IL-7 (IL-7) compared to 
control medium (med) at d12 in 6 biological independent replicates (paired Wilcoxon test, *p=0.03). 
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Figure 4. IL-7 supports superantigen-specific responses. A. Freshly isolated PBMCs were 
rested for 5 days in plain medium (dashed black line) then incubated for one week in IL-7 or control 
medium (respectively: IL-7, black line and, med, dashed black line). At d12, cells were stimulated 
with SEB during an ICS assay to test Ag-specific TNF and IFN- release, compared to 
unstimulated controls (nil). Dot plots show that the frequency of SEB-specific CD4+ T cells 
producing TNF and/or IFN- increased upon exposure to IL-7 in one representative donor. B. 
After subtraction of individual background levels of IFN-+ and TNF+andIFN-+TNF+ CD4 T cells 
detected in unstimulated controls (nil), the percentage of SEB-specific cytokine+ (IFN-+, TNF+, 
IFN-+TNF+ and total) CD4 T cells was evaluated in 17 independent donors in IL-7 (IL-7, open 
triangles) compared to control medium (med, open circles) cultures. The graphs show statistically 
significant increase of the frequency (Log10) of SEB-specific cytokine+ CD4 T cells after IL-7 
culture. All tests are paired Wilcoxon tests with the exception of the single TNF+ analysis (paired 
t-test): *, p≤0.05; **, p≤0.005; ***, p≤0.0005. C. At d12, cells cultured as in (A) were tested for 
CD127 expression in parallel to cytokine release in SEB-specific ICS assay. CD127 expression 
(Log10 MFI, mean fluorescence intensity) is significantly decreased in SEB-specific IFN-+ CD4+ T 
cells exposed to IL-7 (IL-7, downward triangles) compared to control medium (med, upward 
triangles) in 12 independent biological replicates (paired Wilcoxon test, ***p=0.0005). D. Freshly 
isolated PBMCs (d0) w re stimulated with the SEB superantigen (dotted black line) for 5 days (d0-
5). At d5, cells were washed and incubated for one week in IL-7 (IL-7, black line; d5-12) or control 
medium (med, dashed black line; d5-12). At d12, cells were stimulated with SEB (overnight) to test 
Ag-specific TNF and IFN- release, by ICS. Dot plots show that the frequency of SEB-specific 
CD4+ T cells producing TNF and/or IFN- increased upon exposure to IL-7 (IL-7 d5-12, upper 
rows). The graph on the right shows data from the same cultures derived from 6 independent 
biological repeats. Statistically significant accumulation of SEB-specific, cytokine+ CD4+ T cells was 
evaluated using a Wilcoxon matched-pairs signed ranked test (p=0.03). 
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Figure 5. Sensitization by IL-7 promotes pathogen specific CD4+ T cells proliferation in CSA-
sensitive manner. CFSE-labeled PBMCs (A-C) from healthy donors (A-B) or TB patients (C) were 
cultured for 7 days in the absence (med) or in the presence of human recombinant IL-7 (IL-7). A. 
Proliferation of viable CD4 T cells in high density cultures (5x106 cells/ml) was determined by flow 
cytometry after staining with anti-CD4 mAb and TO-PRO-3 (an intercalant agent of DNA entering 
necrotic and apoptotic cells). Dot plots depict the relative CFSE content within the same number of 
viable, TO-PRO-3- CD4+ T cells. B. PBMCs cultured (4x 106 cells/ml) in the presence of IL-7 for 7 
days in the absence or in the presence of CSA. At d7, cells were stained with anti-CD4, 
antiCD45RA and anti-CD62L mAb and the relative CFSE content was analyzed by flow cytometry 
in total CD4 T cells (top row). Fast- (F), Slow- (S), and non-dividing cells were determined based 
on CSA inhibition, as indicated. The percentage of naïve (CD45RA+ CD62Lhi), central memory 
(CD45RA- CD62Lhi), and effector memory (CD45RA- CD62Llo) cells were then investigated in slow- 
compared to fast-proliferating CD4 T cells. C.  Freshly isolated PBMCs were rested for 5 days then 
incubated for one week in IL-7 or IL-7 plus CSA (IL-7+CSA). At d12, cells were stimulated with 
SEB during an ICS assay to test Ag-specific TNF and IFN- release, compared to unstimulated 
controls (refer to Figs. 3-4). Left dot plots show that the IL-7-driven accumulation of CMV- (top) and 
SEB-(bottom)-specific CD4+ T cells producing TNF and/or IFN- is reversed in the presence of 
CSA, by d12. After subtraction of individual background levels of IFN-+, TNF+andIFN-+TNF+ 
CD4 T cells detected in unstimulated controls (nil), the percentage of SEB-specific cytokine+ (IFN-
+, TNF+, IFN-+TNF+ and total) CD4 T cells was evaluated in 15 independent biological repeats 
in IL-7 (open circles) compared to IL-7+CSA cultures (open triangles). The right graphs show 
statistically significant decrease in the frequency (Log10) of SEB-specific cytokine+ (except for IFN-
+) CD4 T cells in the presence of CSA at d12. All tests are paired Wilcoxon tests. *, p≤0.05; **, 
p≤0.005; ***, p≤0.0005 
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